The Impact of Biophoton Therapy on Self-Grown Stem Cells
Launched by FIRST INSTITUTE OF ALL MEDICINES · Feb 26, 2025
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new treatment called biophoton therapy to see if it can help increase the number of stem cells your body naturally produces. Stem cells are important because they can develop into different types of cells in the body and are involved in healing and repair. The trial will involve about 46 volunteers who are interested in boosting their stem cell levels. Participants will be randomly assigned to either receive the biophoton therapy or a placebo (a treatment that looks the same but has no active ingredients) without knowing which one they are getting for the first two weeks.
To be eligible for this trial, you should be between 18 and 70 years old, in good health without major diseases, and able to understand and agree to participate. You should also not have used biophoton devices frequently in the past. If you are interested, expect to sign an informed consent form and follow some study requirements. This trial is currently recruiting participants, so if you meet the criteria and want to be involved, you could help researchers learn more about this potential treatment!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Willing and able to give informed consent for participation in the trial.
- • Is able and willing to comply with all trial requirements.
- • Male or female ages 18-70 years old without major diseases.
- • Participants must not be heavy users of Tesla BioHealing devices; enrollment will be determined by the clinical team based on an evaluation of the participant's prior device usage.
- • Must be fluent in English.
- Exclusion Criteria:
- • Untreated psychiatric disturbances that would affect trial participation as judged by the research medical professional.
- • Is participating in another investigational drug or device trial
- • Had been treated with Stem Cell therapy within a 6-month period.
About First Institute Of All Medicines
The First Institute of All Medicines is a pioneering clinical trial sponsor dedicated to advancing the field of pharmaceutical research and development. Committed to innovation and excellence, the institute focuses on conducting rigorous clinical trials that evaluate new therapeutic interventions across various medical disciplines. By fostering collaboration between researchers, healthcare professionals, and regulatory bodies, the institute aims to accelerate the discovery of safe and effective treatments, ultimately enhancing patient outcomes and improving public health. With a strong emphasis on ethical practices and scientific integrity, the First Institute of All Medicines is at the forefront of transforming healthcare through cutting-edge research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tampa, Florida, United States
Butler, Pennsylvania, United States
Patients applied
Trial Officials
James Z Liu, MD, PhD
Study Chair
First Institute of All Medicines
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported